Anti-HER2-ADC: Interim Phase I data

Interim data from 12 patients with locally advanced or metastatic solid tumors in the dose-escalation part 1 of the 2-part, open-label, European Phase I SYD985.001 trial showed that 0.3, 0.6, 1.2 and ...